RBPs in Hematopoietic Stem Cell Maintenance and Leukemia Initiation: Critical Gaps
Archives of Advances in Biosciences,
Vol. 17 No. 1 (2026),
28 April 2026
,
Page 1-10
https://doi.org/10.22037/aab.v17i1.51400
Abstract
Contex: RNA-binding proteins (RBPs) are key regulators of post-transcriptional gene expression and play essential roles in hematopoietic stem cell (HSC) function. Although major advances have been made in understanding transcriptional regulation in hematopoiesis, the contribution of RBPs to HSC maintenance and leukemia development remains incompletely defined.
Evidence Acquisition: Relevant literature was collected from major scientific databases and high-impact journals, including PubMed, Web of Science, Google Scholar, Nature Portfolio, Elsevier, and related peer-reviewed sources. This systematic review summarizes current findings on the roles of major RBPs and RNA-modifying factors in normal and malignant hematopoiesis, with particular focus on MUSASHI2, IGF2BP family proteins, Lin28b, METTL3, METTL14, ALKBH5, and FTO.
Results: Available studies demonstrate that RBPs regulate RNA processing, stability, translation, and modification, thereby influencing stem cell self-renewal, differentiation, and leukemic transformation. Dysregulation of these factors contributes to leukemia progression, maintenance of leukemia stem cells, and treatment resistance. Emerging evidence also highlights RBP-associated pathways as potential therapeutic targets.
Conclusion: RBPs represent a critical regulatory layer in hematopoietic stem cell biology and leukemia. An improved understanding of these post-transcriptional mechanisms may support the development of more effective therapies that target leukemia stem cells while preserving normal hematopoiesis.
- RNA Binding Proteins
- hematopoietic oncogenesis
- molecular regulation
- M6A modifiers
How to Cite
References
1. de Rooij L, et al. Post-transcriptional regulation in hematopoiesis: RNA binding proteins take control (1). Biochem Cell Biol. 2019 Feb;97(1):10-20. (DOI: 10.1139/bcb-2018-0097)
2. Herrejon Chavez F, et al. RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells. Nat Commun. 2023;14(1):2290. (DOI: 10.1038/s41467-023-37988-7)
3. Raghav PK, Gangenahalli G, Hara T. Editorial: Advancements in hematopoietic stem cell proliferation and self-renewal maintenance. Front Cell Dev Biol. 2025;13: 1607145. (DOI: 10.3389/fcell.2025.1607145)
4. Xie W, et al. Crucial roles of different RNA-binding hnRNP proteins in Stem Cells. Int J Biol Sci. 2021;17(3):807-817. (DOI: 10.7150/ijbs.52977)
5. Minuesa G, et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Int J Biol Sci. 2019;10(1): 2691. (DOI: 10.1038/s41467-019-10520-1)
6. Park SM, et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest, 2015 Mar;125(3):1286-98. (DOI: 10.1172/JCI78440) (PMID)
7. karmakar, S., et al., Integrative genome-wide analysis reveals EIF3A as a key downstream regulator of translational repressor protein Musashi 2 (MSI2). NAR Cancer, 2022. 4(2). (Doi:10.1093/narcan/zcac015)
8. Tran, T.M. and D.S. Rao, RNA binding proteins in MLL-rearranged leukemia. Experimental Hematology & Oncology, 2022. 11(1): p. 80. (Doi:10.1186/s40164-022-00343-5 )
9. Moradi F, et al. Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells. Iran J Basic Med Sci. 2019 Jun;22(6):581-589. (DOI: 10.22038/ijbms.2019.33212.7923)
10. Niu Y, Zhou T, Li Y. Update on the Progress of Musashi-2 in Malignant Tumors. Front Biosci (Landmark Ed). 2025;30(1):24928. (PMID)
11. Kharas MG, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010 Aug;16(8):903-8. (DOI: 10.1038/nm.2187) (PMID)
12. Kwon C, et al. Notch post-translationally regulates ?-catenin protein in stem and progenitor cells. Nat Cell Biol. 2011 Oct;13(10):1244-51. (DOI: 10.1038/ncb2334) (PMID)
13.Lan L, et al. Human oncoprotein Musashi-2 N-terminal RNA recognition motif backbone assignment and identification of RNA-binding pocket. Oncotarget. 2017 Nov;8(1):63–66. (DOI:10.18632/oncotarget.22540) (PMID)
14.Ma S, Qin Y, Ren W. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in hematological diseases. Mol Med. 2024;30(1):165. (DOI: 10.1186/s10020-024-00724-0)
15. Palanichamy JK, et al. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest. 2016 Apr;126(4):1495-511. (DOI: 10.1172/JCI80046) (PMID)
16. Elcheva IA, et al. RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1. Leukemia. 2020 May; 34(5):1354-63. (DOI: 10.1038/s41375-019-0668-4)
17. Cao J, Mu Q, Huang H. The Roles of Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 in Cancer and Cancer Stem Cells. Stem Cells Int. 2018; 2018(1):4217259. (DOI: 10.1155/2018/4217259)
18. Weng H, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec;40(12):1566–82. (DOI: 10.1016/j.ccell.2022.10.012) (PMID)
19. Liu, S., et al., IGF2BP2: an m6A reader that affects cellular function and disease progression. Cellular & Molecular Biology Letters, 2025. 30(1): p. 43. (Doi:10.1186/s11658-025-00723-9 )
20. Li, D., et al., The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential. Int J Mol Sci, 2024. 25(22). (Doi:10.3390/ijms252212150 )
21. Zhang, H., et al., Combating cancer stem cells: RNA m6A methylation and small-molecule drug discovery. 2024. Volume 4 - 2024. (Doi:10.3389/fddsv.2024.1465222)
22. Wang S, et al. Enhancement of LIN28B-induced hematopoietic reprogramming by IGF2BP3. Genes Dev. 2019 Aug;33(15-16):1048–1068. (DOI: 10.1101/gad.324640.119) (PMID)
23. Sang L, et al. The m6A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the MDM2/p53 pathway in acute myeloid leukemia. J Cancer. 2022;13(3):1019–30. (DOI: 10.7150/jca.67598)
24. Chen X, et al. RNA modification in normal hematopoiesis and hematologic malignancies. Blood Sci. 2024;5(11):e787. (PMID)
25. Zhao, W., et al., METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification. Molecular Therapy Nucleic Acids, 2020. 20: p. 1-12. (Doi:10.1016/j.omtn.2020.01.033 )
26.Barbieri, I., et al., Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature, 2017. 552(7683): p. 126-131. (Doi:10.1038/nature24678 )
27. Lee H, et al. Stage-specific requirement for Mettl3-dependent m6A mRNA methylation during haematopoietic stem cell differentiation. Nat Cell Biol. 2019 Jun;21(6):700–709. (DOI: 10.1038/s41556-019-0318-1) (PMID)
28. Cheng, Y., et al., m(6)A RNA Methylation Maintains Hematopoietic Stem Cell Identity and Symmetric Commitment. Cell Rep, 2019. 28(7): p. 1703-1716.e6. (Doi:10.1016/j.celrep.2019.07.032 )
29. Zhou, K.I. and T. Pan, Structures of the m(6)A Methyltransferase Complex: Two Subunits with Distinct but Coordinated Roles. Mol Cell, 2016. 63(2): p. 183-185. (Doi:10.1016/j.molcel.2016.07.005)
30. Wu, X., W. Ye, and Y. Gong, The Role of RNA Methyltransferase METTL3 in Normal and Malignant Hematopoiesis. 2022. Volume 12 - 2022. (Doi:10.3389/fonc.2022.873903 )
31. Esteva-Socias, M. and F. Aguilo, METTL3 as a master regulator of translation in cancer: mechanisms and implications. NAR Cancer, 2024. 6(1). (Doi:10.1093/narcan/zcae009)
32. Kaur, P., et al., Altered Expression of m6A-Associated Genes Is Linked with Poor Prognosis in Pediatric Acute Myeloid Leukemia Patients. Biomolecules, 2025. 15(9). (Doi:10.3390/biom15091238 )
33. Yao, L., et al., RNA methylation in hematological malignancies and its interactions with other epigenetic modifications. Leukemia, 2021. 35(5): p. 1243-1257. (Doi:10.1038/s41375-021-01225-1)
34. iang, L., et al., The m6A methyltransferase METTL14 promotes cell proliferation via SETBP1-mediated activation of PI3K-AKT signaling pathway in myelodysplastic. (Doi:10.1038/s41375-024-02350-3 )
35. Zou, H., et al., RNA-binding protein complex LIN28/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7. Oncogene, 2022. 41(11): p. 1657-1672. (Doi:10.1038/s41388-022-02198-w )
36. Fang, M., et al., M6A Demethylase ALKBH5 in Human Diseases: From Structure to Mechanisms. 2025. 15(2): p. 157. (Doi:10.3390/biom15020157 )
37. Shen, C., et al., RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia. Cell Stem Cell, 2020. 27(1): p. 64-80.e9. (Doi:10.1016/j.stem.2020.04.009)
38. Ye, J. and R. Blelloch, Regulation of pluripotency by RNA binding proteins. Cell Stem Cell, 2014. 15(3): p. 271-280. (Doi:10.1016/j.stem.2014.08.010 )
39. Helgason, G.V., et al., Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets, 2013. 13(7): p. 724-34. (Doi:10.2174/15680096113139990088 )
40. Shi, H., et al., YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Research, 2017. 27(3): p. 315-328. (Doi:10.1038/cr.2017.15)
41. Wang, X., et al., N6-methyladenosine-dependent regulation of messenger RNA stability. Nature, 2014. 505(7481): p. 117-120. ( Doi:10.1038/nature12730 )
42.Gao Y, et al. ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability control. Cell Rep. 2023;42(10):113163. (DOI: 10.1016/j.celrep.2023.113163)
- Abstract Viewed: 90 times
- PDF Downloaded: 10 times